Biotech | October 07, 2025
Lonza expands cell and gene therapy portfolio
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Subscribe To Our Newsletter & Stay Updated
